The Importance of Heterocyclic Compounds in Anti-Cancer Drug Design By Simon Pearce Heterocycles are key structural components of many of the anti-cancer drugs available on the market today. Indeed, of the novel molecular anti-cancer agents approved by the FDA between 2010 and 2015, almost two-thirds contained heterocyclic rings within their… Read More
Raising The Bar On The Biologics Potential Dr Michael Mouradian In the quest for safe, efficacious and profitable therapies, pharma research is changing. There is continued pressure to fill the drug pipeline and, at the same time, globalisation of personalised medicines is complex, expensive and requires a significant time commitment. Read More
3D Cell Culture - A Rapidly Emerging Technique for Drug Discovery By Hannah Gitschier, Dr Ye Fang and Dr Richard M. Eglen The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures. Today, 3D cell cultures are emerging not only as a new tool in… Read More
Monitoring the Balance Between Immune Repression and Stimulation in Cancer Immunotherapy By Dr Peter Schulz-Knappe and Dr Georg Lautscham Cancer is still one of the main causes of death worldwide, yet recent strides towards more effective treatments have been made in the form of new cancer immunotherapies. By weaponising the… Read More
A Marriage of Technologies for Immuno-Oncology In Vivo Studies By Dr Philip Dube Discovering and validating novel therapeutic targets to add to the immuno-oncology arsenal will require refined preclinical models that meet the needs for suitability, scalability and clinical relevancy throughout the various phases of target discovery and drug validation. Read More
Spheroids Rapidly Becoming a Preferred 3D Cell Culture Format By Dr John Comley There are many advantages associated with culturing cells in three-dimensional (3D) versus conventional two-dimensional (2D) tissue culture. Scaffold-free 3D cell culture systems that generate spheroids (and other similar multicellular aggregations) have proved useful as they offer an… Read More
The Discoverome - Creative Destruction of Barriers for Faster to Patient Medicines R&D By Chris Molloy Future medicines discovery begins and ends with patients. Its scope will no longer be limited by the walls of the lab and the moats of major pharma. It will be disease-led, highly collaborative and… Read More
Immuno-Oncology's Biomarker Dilemma: How to add value in an uncertain development landscape By Dr Rachel Laing and Olivier Lesueur Given their ability to promote long-term survival in a percentage of cancer patients, PD-1/PD-L1 checkpoint inhibitors have fast become foundational cancer therapies. But knowing which patients may respond to these drugs… Read More
Kinases and Drug Discovery: Protein Kinases as a Validated Drug Target By Professor Said A. Goueli The role of protein and lipid kinases in cellular physiology and normal and abnormal growth has been well appreciated and has been the focus of intensive research in both academic arenas and pharmaceutical industries. Read More
Filling The Drug Discovery Abyss - Novel Business Models to Push Through the Valley of Death By Dr Swati Prasad, Dr Charles McOsker, Professor Kathryn Chapman and Dr Michael Foley Over the past three years, the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have approved… Read More
An Update on Hepatitis B Therapies By Dr John Sullivan-Bolyai The hepatitis B crisis is a worldwide unmet medical need. Hepatitis B (HBV) is the cause of a silent epidemic that has resulted in a worldwide healthcare crisis. Despite the significant burden it places on communities across the globe, hepatitis… Read More
I Robot. I, The Future - Robotics Within and Beyond The Lab Richard Holland The Pistoia Alliance (whose membership includes most of the world’s major pharmaceutical companies, technology vendors and publishers active in the life science R&D sector), is keenly interested in discovering the ways in which innovation through pre-competitive… Read More
CRISPR Cas9: Transforming Gene Editing in Drug Discovery Labs By Dr John Comley It is evident from a recent market survey on gene editing in drug discovery that CRISPR/Cas9 is now recognised as the superlative method when attempting a gene knockout or when introducing defined mutations, insertions or modifications to… Read More
Cell Therapy & Gene Therapy - The emerging fourth pillar of healthcare systems By Keith Thompson As the CEO of an organisation that deals exclusively in cell therapy and gene therapy, it is no surprise that I would champion the emergence of these products as the fourth pillar of medicine… Read More
Breath Based Biomarker Detection & Breath Biopsy - Informing drug development and future treatment regimes By Billy Boyle and Dr Mike Murphy The recent approval of the first liquid biopsy test for the diagnosis of non-small cell lung cancer (NSCLC) demonstrates how biomarker-based detection tools are becoming important components of… Read More
By Dr Thomas Mehrling Increasingly, oncology agents are being used in combination. However, with complications such as drug resistance and unfavourable side-effect profiles, researchers have been looking for new ways to enhance treatment effect and tolerability. New fusion technology molecules appear to offer a beneficial synergy, but will this withstand… Read More